Opinion|Videos|July 12, 2024
MajesTEC-1 and the Value of Long-Term Follow-Up Data from ASCO 2024
Dr Garfall, MD, provides further insights around the MajesTEC-1 study.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide your key takeaways from this study. How do these updated results impact the potential use of teclistamab in the management of RRMM?
- What is the value of long-term follow-up data in multiple myeloma? How does this impact treatment regimens?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Congress Unveils Massive Funding Bill to Avert Shutdown
2
Novel CLL Therapies Prompt New Treatment Considerations
3
ctDNA Positivity Associated With Worse Survival, Higher Recurrence Risk in Patients With NSCLC
4
Early Data Show Feasibility of in Vivo CAR T Therapy in Multiple Myeloma
5
